-transparent.png){kind=logo}
A 39-year-old Japanese female who had been followed as chronic myelogenous leukemia (CML) since 1984 was admitted to our hospital because of dizziness. On admission, platelet count markedly increased (245 X 10(4)/microliters) in spite of daily administration of busulfan 2 mg. She was diagnosed as accelerated phase CML with thrombocytosis. So we tried to use interferon alpha (IFN-alpha) finally given in a dose of 9 X 10(6) U daily by subcutaneous injection. After that, platelet count decreased to 70 X 10(4)/microliters and megakaryocyte count in bone marrow decreased from 887.5/microliters to 395.7/microliters. But we had to stop IFN-alpha because of severe side effects.
Related Publications
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
December 1989,
Asian Pacific journal of allergy and immunology,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
July 1990,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
December 1983,
Annals of internal medicine,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
November 2002,
Cancer letters,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
April 2000,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
January 1996,
Leukemia,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
January 1994,
Medical and pediatric oncology,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
January 2007,
Seminars in hematology,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
April 1997,
Leukemia,
G Koike, and
T Otsuka, and
T Shibuya, and
Y Niho
October 1995,
The American journal of medicine,
